File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Dyslipidaemia in patients with lupus nephritis

TitleDyslipidaemia in patients with lupus nephritis
Authors
Issue Date2011
PublisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEP
Citation
Nephrology, 2011, v. 16 n. 5, p. 511-517 How to Cite?
AbstractAim: There is little data on the prevalence and severity of dyslipidaemia in Asian patients with lupus nephritis (LN). Whether the dyslipidaemia in LN patients differs from subjects with comparable levels of renal impairment also remains undefined. Methods: Lipid profiles of 100 Chinese patients with quiescent LN (age 46.3 ± 9.3 years, 83% female, maintenance prednisolone dose 5.80 ± 2.43 mg/day) were studied and compared with 100 controls who had non-lupus non-diabetic chronic kidney diseases (CKD), matched for sex, age and renal function. Results: LN patients and CKD controls had similar renal function and proteinuria, while blood pressure was higher in controls. Twenty-five percent of LN patients and 17% of controls were receiving statin treatment. Despite this, 59% of LN patients and 46% CKD controls showed abnormal lipid parameters (P = 0.066). LN patients showed higher levels of total cholesterol (TC) and triglycerides (TG) than controls (5.28 ± 0.12 vs 4.86 ± 0.08 mmol/L, P = 0.004; and 1.62 ± 0.12 vs 1.20 ± 0.07 mmol/L, P = 0.002, respectively). More LN patients had abnormal TC, TG or low-density lipoprotein cholesterol (LDL-C) (54%, 16% and 38%; P = 0.016, = 0.005 and = 0.021, respectively). Hydroxychloroquine (HCQ) treatment was associated with lower TC, LDL-C and HDL-cholesterol. Conclusion: Dyslipidaemia is prevalent in LN patients and is more severe than controls with a similar degree of CKD despite disease quiescence, low steroid dose and low level of proteinuria. Concomitant corticosteroid and renal impairment are likely contributing factors. HCQ treatment is associated with reduced severity of dyslipidaemia in LN patients. Both systemic lupus erythematosus and chronic kidney disease are associated with excess vascular mortality. In this significant cohort of Asian patients with lupus nephritis, Chong et al. show that dyslipidaemia is common, even in inactive lupus nephritis, more common than in controls with a similar degree of chronic kidney disease. © 2011 Asian Pacific Society of Nephrology.
Persistent Identifierhttp://hdl.handle.net/10722/163381
ISSN
2015 Impact Factor: 1.796
2015 SCImago Journal Rankings: 0.894
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChong, YBen_US
dc.contributor.authorYap, DYen_US
dc.contributor.authorTang, CSen_US
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:30:42Z-
dc.date.available2012-09-05T05:30:42Z-
dc.date.issued2011en_US
dc.identifier.citationNephrology, 2011, v. 16 n. 5, p. 511-517en_US
dc.identifier.issn1320-5358en_US
dc.identifier.urihttp://hdl.handle.net/10722/163381-
dc.description.abstractAim: There is little data on the prevalence and severity of dyslipidaemia in Asian patients with lupus nephritis (LN). Whether the dyslipidaemia in LN patients differs from subjects with comparable levels of renal impairment also remains undefined. Methods: Lipid profiles of 100 Chinese patients with quiescent LN (age 46.3 ± 9.3 years, 83% female, maintenance prednisolone dose 5.80 ± 2.43 mg/day) were studied and compared with 100 controls who had non-lupus non-diabetic chronic kidney diseases (CKD), matched for sex, age and renal function. Results: LN patients and CKD controls had similar renal function and proteinuria, while blood pressure was higher in controls. Twenty-five percent of LN patients and 17% of controls were receiving statin treatment. Despite this, 59% of LN patients and 46% CKD controls showed abnormal lipid parameters (P = 0.066). LN patients showed higher levels of total cholesterol (TC) and triglycerides (TG) than controls (5.28 ± 0.12 vs 4.86 ± 0.08 mmol/L, P = 0.004; and 1.62 ± 0.12 vs 1.20 ± 0.07 mmol/L, P = 0.002, respectively). More LN patients had abnormal TC, TG or low-density lipoprotein cholesterol (LDL-C) (54%, 16% and 38%; P = 0.016, = 0.005 and = 0.021, respectively). Hydroxychloroquine (HCQ) treatment was associated with lower TC, LDL-C and HDL-cholesterol. Conclusion: Dyslipidaemia is prevalent in LN patients and is more severe than controls with a similar degree of CKD despite disease quiescence, low steroid dose and low level of proteinuria. Concomitant corticosteroid and renal impairment are likely contributing factors. HCQ treatment is associated with reduced severity of dyslipidaemia in LN patients. Both systemic lupus erythematosus and chronic kidney disease are associated with excess vascular mortality. In this significant cohort of Asian patients with lupus nephritis, Chong et al. show that dyslipidaemia is common, even in inactive lupus nephritis, more common than in controls with a similar degree of chronic kidney disease. © 2011 Asian Pacific Society of Nephrology.en_US
dc.languageengen_US
dc.publisherBlackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/NEPen_US
dc.relation.ispartofNephrologyen_US
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCross-Sectional Studiesen_US
dc.subject.meshDyslipidemias - Drug Therapy - Epidemiology - Etiologyen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLipids - Blooden_US
dc.subject.meshLupus Nephritis - Blood - Complicationsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.titleDyslipidaemia in patients with lupus nephritisen_US
dc.typeArticleen_US
dc.identifier.emailYap, DY:desmondy@hku.hken_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityYap, DY=rp01607en_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1111/j.1440-1797.2011.01456.xen_US
dc.identifier.pmid21355950-
dc.identifier.scopuseid_2-s2.0-79959901598en_US
dc.identifier.hkuros209996-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-79959901598&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue5en_US
dc.identifier.spage511en_US
dc.identifier.epage517en_US
dc.identifier.isiWOS:000292163500008-
dc.publisher.placeAustraliaen_US
dc.identifier.scopusauthoridChong, YB=24773094400en_US
dc.identifier.scopusauthoridYap, DY=25958532000en_US
dc.identifier.scopusauthoridTang, CS=8681865300en_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats